A pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products.

Dr. Reddy's

Purple Health

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services
including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by:
Accessing https://drreddys.ethicspoint.com. 
Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. 
Writing to complianceofficer@drreddys.com or chiefombudsperson@drreddys.com. 
 

MAPE Advisory Group

Dr. Reddy's Laboratories

Pleased to see our work in supporting women in the workforce in non-traditional areas was highlighted recently. The story described our all-women team initiative at one of our formulation units at Baddi, Himachal Pradesh. The all-women team was trained as part of our Self-Managed Team (SMT) initiative. A concept pioneered by us over two decades ago, SMT involves recruiting and skilling youth with 10+2 qualifications to create employability for youth from rural areas closest to our sites. The all-women team is an initiative aimed towards the empowerment and progress of women in a manufacturing sector such as pharmaceuticals. The article notes, “Apart from excelling at established roles, becoming adept at secondary packing operations, the [all-women team at Dr. Reddy's] also embarked on new initiatives such as taking charge of the sachet packing line of our other formulation unit in Baddi. What began as a single line managed entirely by women was soon expanded with the addition of a second line. The pharmaceutical company has also introduced all-women night shift teams, providing them with transportation facilities, dedicated all-women HR support teams, and attendants to accompany them”.

To read the article, please visit: https://shorturl.at/IW9CX

To read more about our ESG goals on gender parity, please visit: http://bit.ly/3ZMMWRM

#WeAreDrReddys #SustainabilityXDrReddys
#GoodHealthCantWait
#SDG5 (gender equality) 
#SDG10 (reduced inequalities)

Our team had an amazing experience showcasing our innovations and networking with industry experts and leaders. We're excited to share some memorable moments from the event with you all.

We look forward to continuing these meaningful conversations and collaborations. Let's keep pushing the boundaries of innovation together!

#DrReddysXSustainability #GoodHealthCantWait #WeAreDrReddys #DrReddysAPI #ESG #Sustainability #APIPartner #Pharmaceuticals
#CPHI2024 #CPHI #Shanghai #China #CPHIChina2024

We are pleased to announce the launch of our drug-free non-invasive migraine management device Nerivio® in the UK. In recent months, we have launched Nerivio® in India, Germany, South Africa and Spain. Nerivio® is the first USFDA-cleared and CE marked portable Remote Electrical Neuromodulation (REN) technology for the prevention and/or treatment of acute migraine (with or without aura) in adults and adolescents (≥ 12 years). It is placed on the upper arm and controlled by a mobile app, making it a convenient and portable device.

In the UK, one in seven people suffer from migraine; a complex, severe, and painful long-term health condition*.  Nerivio® unlocks a new solution for migraine
patients, a significant step towards migraine treatment landscape in the UK. Visit here for more details: 
https://lnkd.in/gWnGk6yu

*https://lnkd.in/gi98z73Z

[Nerivio® is a prescription-based product. Patients are advised to consult their neurologists on the use of the device and management of migraine.]

Our Safety, Health, Environment and Sustainability (SHE&S) team continues to extend #WorldEnvironmentDay into a month of awareness activities. In line with our theme for last week, "Water Efficiency & Management," our colleagues participated in activities such as Tool Box Talks on shop floors on water conservation and in trainings given by our Water Ambassadors. 70 Water Ambassador training sessions have been conducted across our sites and they in turn spread awareness to over 1,600 people within the organisation. We also conducted a webinar on "Navigating RO Systems for Environmental Excellence by Dupont" and 48 Gemba walks, where critical issues and leaks were identified and closed. Our colleagues also participated in giving their unique ideas for water conservation. Over 350 people participated in a quiz on water conservation and environmental compliance across sites. Students from Samskriti Global School-Vizag were trained on water and waste management by our colleagues in Visakhapatnam, India.

Here are some glimpses of the activities.
 
#WeAreDrReddys #EnvironmentMonth #GoodHealthCantWait #DrReddysXSustainanbility #ESG

Domain Not Resolving

DNSSEC

Font Awesome

Organization Schema

US Privacy User Signal Mechanism

reCAPTCHA

IPv6

Apache

jsDelivr

Apple Mobile Web App Capable

Chief Commercial Officer, North America Generics

Milan Kalawadia

VP and CIO/ CDO (North America), Digital & Process Excellence

Sanjay Choubey

Assistant General Counsel - Compliance, Investigations and Litigation

Scott Hollander

Vice President and Regional General Counsel, the Americas

Vanessa Brill

Vice President and Head of Strategy, Innovation and Business Development, North America Generics

Abhishek Mukhopadhyay, Ph.D., CFA

Associate Vice President - Sales

Larry Matthews

Business Management

Mayank Nagar

Executive Vice President, Head Formulations R&D, North America/ Europe

Sridhar Desikan

Director & Group HR Lead - India Business

Aaron D'Souza

Marketing and Product

Abeera Sharma

Srikanth Annadata

Ashok Ganguly

Satish Reddy

Sridar Iyengar

G.V. Prasad

Chief Executive Officer, Co-Chairman of the Board, Director & Managing Director

Prasanna Kumar Thenneti

Head, Regulatory Affairs

Archana Bhaskar

Executive Vice President & Executive

Anji Reddy

Founder

Erez Israeli

Chief Executive Officer

Marc Kikuchi

Saumen Chakraborty

Chief Financial Officer, Finance & Executive

Christel Kronig

Senior Analytical Scientist

Biotechnology Public Companies With More Than 500 Employees

Andhra Pradesh Medical Companies

Medical Public Companies With More Than $500 in Revenue

Asia Public Companies With More Than $1B in Revenue

Dr. Reddy’s Laboratories  is an integrated pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) business and custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL’s new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma.

Life Insurance Corporation

Post-IPO Equity - Dr. Reddy’s Laboratories

Hyderabad

Andhra Pradesh

India

Asia

Dr. Reddy’s Laboratories

Telangana government inks MoUs for ₹5,260 crore investments in Pharma City

India Active Pharmaceutical Ingredients Market Size on Track to Surpass USD 37.11 Billion by 2032 at a 12.33% CAGR | VMR

Six pharma companies sign MoUs with Telangana govt for Pharma City

Dr Reddy's, Aurobindo Pharma, others ink pact with Telangana govt to set up facilities in Pharma City

High Potency APIs Market Size on Track to Surpass USD 65273.9 Million by 2032 at a 10.6% CAGR | VMR

Global pharma licensing agreements see a slow-down, says report

Stocks to watch: Adani Group stocks, Wipro, Bharti Airtel, JSW Steel among stocks that could be in focus today

Dr Reddy's Labs tanks over 3% after USFDA inspects Hyderabad API facility

USFDA issues seven observations to Dr Reddy's Hyderabad manufacturing plant

Dr. Reddy’s API unit issued Form 483 with 7 observations by U.S. FDA

Dr. Reddy's Laboratories offers a wide range of generic medications across various therapeutic areas, providing affordable treatment options for patients worldwide.

The company produces and supplies APIs, which are the active components used in the manufacturing of pharmaceutical drugs.

Dr. Reddy's develops biosimilars, which are biologic medical products highly similar to already approved reference products, to provide cost-effective alternatives.

The company offers OTC medications that are available without a prescription, catering to common health issues.

Dr. Reddy's develops proprietary medications, which are unique formulations or new chemical entities, to address specific medical needs.

The company is expanding into consumer health products, including dietary supplements and health-related products for general well-being.

news impact assignment basic	general
public peers	general	Jul 11, 2024 6:28 PM	d8fce2a5
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	c5c906a9
crunchbase profile	general	Nov 25, 2024 11:39 AM	41d4f9c9
li profile	general	Jul 11, 2024 6:28 PM	3089d3a3
translate crunchbase fundingrounds	general	Nov 25, 2024 2:16 PM	83236ef6
peers	general	Jul 11, 2024 6:28 PM	b1361f61
news basic	general	Jul 11, 2024 6:28 PM	78bb64e5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:DRREDDYS

Dr. Reddy's